• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis

News
Article

Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.

The Food and Drug Administration (FDA) has granted fast track designation for potential use of the positron emission tomography (PET) agent 18F(florbetaben) in the detection of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis.

Currently indicated for the estimation of beta amyloid neuritic plaque density on PET scans for patients being assessed for cognitive decline, 18F(florbetaben) (Neuraceq, Life Molecular Imaging) is currently the subject of a phase 3 multicenter trial for detection of cardiac amyloidosis, according to Life Molecular Imaging.

PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis

The positron emission tomography (PET) agent 18F(florbetaben) (Neuraceq, Life Molecular Imaging) is currently being evaluated in a phase 3 multicenter trial for detection of cardiac amyloidosis. The radiopharmaceutical 18F(florbetaben) was recently granted with the fast track designation by the FDA for the detection of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis. (Images courtesy of the Journal of Nuclear Medicine.)

“Diagnosing cardiac AL amyloidosis is complex and challenging,” added Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. “(18F)florbetaben PET imaging of patients with suspected cardiac amyloidosis has the potential to streamline the diagnostic process, providing earlier and appropriate access to therapy and improved monitoring of such interventions.”

Noting the safety profile of the radiopharmaceutical, Life Molecular Imaging said clinical trial research involving nearly 1,100 administrations of 18F(florbetaben) revealed that the most common adverse drug reactions were injection site pain in 3.4 percent of patients and injection site erythema in 1.7 percent of patients.

Recent Videos
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Related Content
© 2025 MJH Life Sciences

All rights reserved.